SCHEMBL29616776

SCHEMBL29616776

CCOc1cccc(N2C[C@@H]3CC(C)(C)[C@H]2CC3=O)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACACB O00763 2/20 0.38
NPY1R P25929 3/20 0.37
GAA P10253 1/20 0.37
NOTUM Q6P988 2/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
NSD2 O96028 1/20 0.35
POLB P06746 1/20 0.35
DNMT1 P26358 1/20 0.35
BLM P54132 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22555749 1.00 SMN1; SMN2 (0.44) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL22567521 1.00 SMN1; SMN2 (0.44) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL22555792 0.87 LMNA (0.43) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL20898249 0.87 LMNA (0.43) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL22567520 0.87 LMNA (0.43) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL22567345 0.87 LMNA (0.43) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL22555805 0.83 MEN1 (0.44) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL29616666 0.83 MEN1 (0.44) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL22567593 0.80 ALDH1A1 (0.36) SMN1; SMN2MAPTHSD17B10ALDH1A1L3MBTL1
SCHEMBL22555808 0.80 ALDH1A1 (0.36) SMN1; SMN2MAPTHSD17B10ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060360-B2 Lysyl oxidase inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-08-13 US disclosed
US-20220289757-A1 LYSYL OXIDASE INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-09-15 US disclosed
US-11325915-B2 Lysyl oxidase inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060360-B2 Lysyl oxidase inhibitors LOXL1, LOXL2, LOXL3 SMN1; SMN2 4751/4885MEN1 4491/4885KMT2A 2125/4885
US-20220289757-A1 LYSYL OXIDASE INHIBITORS LOXL1, LOXL2, LOXL3 SMN1; SMN2 4751/4885MEN1 4491/4885KMT2A 2125/4885
US-11325915-B2 Lysyl oxidase inhibitors LOXL1, LOXL2, LOXL3 SMN1; SMN2 4751/4885MEN1 4491/4885KMT2A 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.